Bavarian Nordic defies new failure and maintains efforts in cancer area

Even though Bavarian Nordics' phase II trial with a vaccine candidate against the cancer disease chordoma failed, the firm's management sees enough potential within the oncology portfolio to keep the work going, although it is still uncertain how this will pan out.

Bavarian Nordic's Executive Vice President and Chief Scientific Officer Paul Chaplin. | Photo: Bavarian Nordic / PR

In recent years, Bavarian Nordic has had some trouble in the cancer area with three failures to follow. Firstly, Prostvac, then CV301 and in December 2020 BN-Brachyury failed as a therapeutic vaccine against he rare cancer disease chordoma.

In spite of the failures, Bavarian Nordic is far from ready to leave the cancer area and BN-Brachyury.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs